Literature DB >> 24534640

Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning.

Akira Iizuka1, Masaru Komiyama1, Chie Oshita1, Akiko Kume1, Tadashi Ashizawa1, Koichi Mitsuya2, Nakamasa Hayashi2, Yoko Nakasu2, Ken Yamaguchi1, Yasuto Akiyama3.   

Abstract

Antibody direct cloning from single B cells is simple and efficient and has been successful in antibody identification of infectious diseases. However, although a recent whole-exome sequencing revealed abundant heterogeneic mutation accumulation in cancers, identification and synthesis of autoantibodies against specific cancer-associated antigens is still difficult in cancer patients owing to the very small number of B cells producing autoantibodies. In the present study, to identify autoantibodies targeting tumor antigens, we measured the titer of autoantibodies in high-grade glioma patients' plasma and identified two patients with elevated autoantibodies to a few transmembrane proteins. Specific B cells producing autoantibody against vascular endothelial growth factor receptor (VEGFR) 2 were immunostained with labeled protein and anti-human IgG antibody, and then collected by a single cell sorter. Finally, 22 antibody genes were successfully identified using direct IgG cloning from single B cell mRNA, and two antibody clones were found to have significant VEGFR2-specific binding affinity. The current direct human IgG gene cloning technique for identifying human antibodies derived from IgG-memory B cells avoids time-consuming procedures such as phage display-based antibody-library screening, and therefore may be applicable to identifying human autoantibodies in a variety of disorders including cancers even when antibody elevation is not detected because of a very small number of memory B cells.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Direct antibody gene cloning; Human IgG ELISA; Human monoclonal antibody; Single B cell; VEGFR2

Mesh:

Substances:

Year:  2014        PMID: 24534640     DOI: 10.1016/j.imlet.2014.02.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  3 in total

Review 1.  New approaches for cancer immunotherapy.

Authors:  Ayfer Karlitepe; Ozgun Ozalp; Cigir Biray Avci
Journal:  Tumour Biol       Date:  2015-05-02

2.  Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.

Authors:  Michael Zhang; Gregor Hutter; Suzana A Kahn; Tej D Azad; Sharareh Gholamin; Chelsea Y Xu; Jie Liu; Achal S Achrol; Chase Richard; Pia Sommerkamp; Matthew Kenneth Schoen; Melissa N McCracken; Ravi Majeti; Irving Weissman; Siddhartha S Mitra; Samuel H Cheshier
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

3.  Detection of Autoantibodies to Vascular Endothelial Growth Factor Receptor-3 in Bile Duct Ligated Rats and Correlations with a Panel of Traditional Markers of Liver Diseases.

Authors:  Florent Duval; Delia Elva Cruz-Vega; Ivonne González-Gamboa; María Teresa González-Garza; Fernando Ponz; Flora Sánchez; Gabriela Alarcón-Galván; Jorge E Moreno-Cuevas
Journal:  Dis Markers       Date:  2016-04-24       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.